{"created":"2023-05-15T14:56:44.756014+00:00","id":77012,"links":{},"metadata":{"_buckets":{"deposit":"62e59ed3-f484-49f8-9393-149e89e9f302"},"_deposit":{"created_by":1,"id":"77012","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"77012"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00077012","sets":["10:29"]},"author_link":["789708","789705","789707","789706"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2019-09-28","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Gastric cancer (GC) is a leading cause of cancer related death worldwide. Because of the asymptomatic at early stage, GC patients often already have distant metastasis at the time of diagnosis, and 4-14% of them are liver metastasis of GC (LMGC) with dismal prognosis. Trastuzumab, a humanized anti-HER2 monoclonal antibody, has been clinically used for the treatment of HER2-positive (HER2+) GC, which account for about 20% of GC. \nRecently, targeted alpha therapy (TAT) is getting higher attention as a novel therapeutic option for metastasis, benefited from the combination of advantages of antibodies, cancer specific targeting, and alpha particles, high cell killing effects and short range. Astatine 211 (At211) is one of the attractive alpha- emitter for clinical use. \nIn this study, we investigated the therapeutic efficacy and toxicity of TAT with At211-trastuzumab using preclinical HER2+ LMGC mice model. Our results provided the proof of concept that TAT with At211-trastuzumab has high potential as a novel therapeutic option against HER2+ LMGC.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第78回日本癌学会学術総会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Li, Huizi"}],"nameIdentifiers":[{"nameIdentifier":"789705","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hasegawa, Sumitaka"}],"nameIdentifiers":[{"nameIdentifier":"789706","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Li, Huizi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"789707","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hasegawa, Sumitaka","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"789708","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"HER2高発現胃がん肝転移に対する新規標的α線内用療法","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"HER2高発現胃がん肝転移に対する新規標的α線内用療法"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-10-01"},"publish_date":"2019-10-01","publish_status":"0","recid":"77012","relation_version_is_last":true,"title":["HER2高発現胃がん肝転移に対する新規標的α線内用療法"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-16T00:04:02.548270+00:00"}